Novo Nordisk has reported that diabetes drug candidate Degludec has met the primary objectives of two clinical trials.

The Danish drug-manufacturer has revealed that Degludec improved long-term blood sugar control and reduced hypoglycaemia risks compared to alternative treatments in the year-long Phase IIIa studies.

The drug is expected to be a major financial driver for the company, which plans to launch the drug in 2013.